Newer’ antihypertensive therapy reduces cardiovascular events compared to ‘older’ drugs, according to the recently published Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA). The results showed that antihypertensive therapy based on the calcium channel blocker amlodipine, with the ACE inhibitor perindopril added as required, reduced cardiovascular events compared with treatment based on the beta-blocker atenolol. In this article, we review what the findings mean for primary care management of high blood pressure and put them in perspective.
